[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AlfredoM617 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::47191740.png) Alfredo M [@AlfredoM617](/creator/twitter/AlfredoM617) on x XXX followers
Created: 2025-07-14 19:36:04 UTC

Efficacy: Among the Best Observed in the Field $VKTX

In its 13-week Phase X VENTURE trial, VK2735’s injectable version delivered up to XXXX% weight loss, with XX% of patients achieving ≥10% weight loss — comparable to or better than tirzepatide, and clearly outpacing semaglutide (Wegovy).

Key highlights:

Placebo-adjusted weight loss: ~13.1% at XX mg weekly in just XX weeks

Progressive loss: No plateau by Week 13; trajectory suggests even higher efficacy with longer dosing

Durability: Over XX% of weight lost was retained X weeks after cessation, hinting at infrequent maintenance dosing potential (monthly or longer)

Oral VK2735, in its Phase X trial, demonstrated up to XXX% weight loss in just XX days (100 mg daily). Weight loss was still evident four weeks post-treatment, and no vomiting was reported — a massive improvement over oral semaglutide or Pfizer’s discontinued danuglipron.


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1944843356825346229/c:line.svg)

**Related Topics**
[$mngl](/topic/$mngl)
[wegovy](/topic/wegovy)
[weight loss](/topic/weight-loss)
[$vktx](/topic/$vktx)

[Post Link](https://x.com/AlfredoM617/status/1944843356825346229)